Objectives: To compare the detection performance of [Ga]DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) and [F]FDG PET/CT for patients with various benign diseases and that of [Ga]DOTA-FAPI-04 PET/CT and [Tc]MDP single-photon emission computed tomography/computed tomography (SPECT/CT) for patients with benign bone lesions.
Methods: This prospective study included 89 patients who underwent [F]FDG and [Ga]DOTA-FAPI-04 PET/CT and 22 patients who underwent [Tc]MDP SPECT/CT and [Ga]DOTA-FAPI-04 PET/CT. Detection performance of [Ga]DOTA-FAPI-04, [F]FDG PET/CT, and [Tc]MDP SPECT/CT for benign lesions was compared using the T/B value, T value, and true positive rate. Paired sample t-tests were conducted for comparisons.
Results: This study comprised 53 men and 58 women (mean age, 53 ± 15.75 years). [Ga]DOTA-FAPI-04 demonstrated a higher uptake and detection rate for fibrotic disease (SUVmax [FAPI vs FDG: 6.26 ± 1.61 vs 2.38 ± 1.26], p1 < 0.001; T/B value [FAPI vs FDG: 9.38 ± 2.78 vs 1.95 ± 1.33], p2 < 0.001; and true positive rate 100% vs 26.3%), infectious disease (T/B value [FAPI vs FDG: 14.15 ± 12.42 vs 6.70 ± 5.87], p2 < 0.05; and true positive rate 94% vs 82%), and benign tumor (T/B value [FAPI vs FDG: 6.49 ± 5.85 vs 1.96 ± 2.03], p2 < 0.05; and true positive rate 70% vs 52%) than [F]FDG. [Ga]DOTA-FAPI-04 demonstrated a lower uptake and a comparable detection rate for benign bone disease (T/B value [FAPI vs FDG: 5.46 ± 2.91 vs 23.58 ± 15.37], p < 0.001; and true positive rate 90% vs 99%) than [Tc]MDP.
Conclusion: [Ga]DOTA-FAPI-04 could be used as a benign disease imaging agent to complement traditional nuclide imaging agents.
Clinical Relevance Statement: Our study showed that [Ga]DOTA-FAPI-04 PET/CT could provide reliable imaging evidence for clinical detection and diagnosis of various benign lesions, such as inflammatory, infectious, fibrotic diseases, and benign tumors.
Key Points: • [Ga]DOTA-FAPI-04 demonstrated a higher uptake and detection rate for fibrotic disease, infectious disease, and benign tumor than [F]FDG. • [Ga]DOTA-FAPI-04 demonstrated an equivalent detection efficacy to [F]FDG for inflammatory diseases. • [Ga]DOTA-FAPI-04 demonstrated a lower uptake and a comparable detection rate for benign bone disease than [Tc]MDP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00330-023-09952-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ga-DOTA-FAPI-04 and F-FDG PET/CT: a head-to-head comparison for peritoneal carcinomatosis diagnostic accuracy.
Abdom Radiol (NY)
January 2025
Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Purpose: The study aimed to compare the diagnostic accuracy of Ga-DOTA-FAPI-04 (Ga-FAPI) and F-FDG PET/CT for peritoneal carcinomatosis (PC) in patients with various types of cancer.
Methods: The study enrolled 113 patients with suspected peritoneal malignancy, each of whom underwent Ga-FAPI and F-FDG PET/CT scans. Lesions in all patients were confirmed through pathology or radiological follow-up.
Preoperative assessment of pancreatic cancer with [Ga]Ga-DOTA-FAPI-04 PET/MR versus [F]-FDG PET/CT plus contrast-enhanced CT: a prospective preliminary study.
Eur J Nucl Med Mol Imaging
February 2025
Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, 168 Changhai Road, Yang Pu District, Shanghai, 200433, China.
Purpose: To assess the diagnostic performance of [Ga]Ga-DOTA-FAPI-04 PET/MR imaging in the preoperative evaluation of pancreatic cancer and compare it with that of [F]-FDG PET/CT plus contrast-enhanced CT (CECT).
Methods: Thirty-one patients with pancreatic cancer underwent preoperative [Ga]Ga-DOTA-FAPI-04 PET/MR, [F]-FDG PET/CT, and CECT imaging. Two nuclear medicine physicians independently reviewed two sets of images (set 1, [Ga]Ga-DOTA-FAPI-04 PET/MR; set 2, [F]-FDG PET/CT plus CECT) and reached a consensus on tumour resectability, N staging (N0 or N positive) and M staging (M0 or M1).
In medullary thyroid carcinoma (MTC), distant metastases have few therapeutic options with low success rates and substantial toxicity in many patients, warranting exploration of alternate systemic treatments with fewer adverse effects. The fibroblast activation protein inhibitor (FAPI)-based PET/CT opens new avenues for several cancers, including MTC. A case of MTC with varying tracer avidity and interlesional heterogeneity on 18 F-FDG, 68 Ga-DOTATATE, and 68 Ga-DOTA-FAPI-04 PET/CT imaging is presented.
View Article and Find Full Text PDFExploration the feasibility and additional value of [F]FDG/[Ga]Ga-FAPI-04 dual-low-activity-tracer one-stop total-body PET imaging at 34 min post-injection of [Ga]Ga-FAPI-04.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Article Synopsis
- The study aimed to assess the feasibility and effectiveness of a one-stop dual-tracer PET/CT imaging method using [F]FDG and [Ga]Ga-FAPI-04 for cancer evaluation at a short interval post-injection.
- The results showed that the one-stop imaging method provided higher tumor-to-normal ratios (TNRs) compared to the traditional two-day protocol, with better lesion detectability and reduced radiation exposure.
- Overall, one-stop FDG-FAPI PET/CT could offer sufficient diagnostic information for clinical use and is a promising alternative to longer imaging protocols.
Article Synopsis
- - A case study is presented involving a man diagnosed with malignant melanoma, who showed a thickened right breast during a PET/CT scan using 68Ga-DOTA-FAPI-04.
- - The scan indicated increased tracer uptake, suggesting a possible issue with the breast tissue.
- - However, follow-up ultrasound tests revealed that the thickening was benign gynecomastia and did not indicate any signs of malignancy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!